

**Notice to 340B covered entities regarding CALQUENCE replenishment and CALQUENCE capsule formulation discontinuation**

Two different formulations of CALQUENCE (capsules and tablets) are currently available in the United States.

AstraZeneca will discontinue distribution of the CALQUENCE capsule NDC listed below by December 31, 2022.

In light of this discontinuance, AstraZeneca is hereby providing notice that it voluntarily agrees that covered entities utilizing virtual inventory management with a 340B inventory replenishment model may count accumulations of the CALQUENCE capsule NDCs toward replenishment of equal quantities of the corresponding CALQUENCE tablet NDC.

<b>CALQUENCE® (acalabrutinib)</b>	<b>Strength</b>	<b>NDC</b>	<b>Order Quantity</b>
Tablet	100 mg	0310-3512-60	60-count bottle
Capsule	100 mg	0310-0512-60	60-count bottle

Please direct questions to: [azusgovernmentpricing@astrazeneca.com](mailto:azusgovernmentpricing@astrazeneca.com)